Achillion 205: An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471

Project: Research project

Project Details

StatusActive
Effective start/end date5/16/19 → 8/31/50

Funding

  • Achillion Pharmaceuticals, Inc.